Evidence map›Paper›PMID 30177807›Full record

ArticleNature nanotechnology2018

Neutrophil membrane-coated nanoparticles inhibit synovial inflammation and alleviate joint damage in inflammatory arthritis.

Qiangzhe Zhang, Diana Dehaini, Yue Zhang, Julia Zhou, Xiangyu Chen, Lifen Zhang, Ronnie H Fang, Weiwei Gao, Liangfang Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Nature nanotechnology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 350 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
350citing papers in PubMed, 1 pooled it
48.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

350 citing papers in PubMed, 1 synthesis or guideline pooled it, 925 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. A Neutrophil Membrane-Encapsulated Pd/hCeOAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  5. Review
  6. Mesenchymal Stromal Cell-Based Cell-Drug Conjugates for the Treatment of Acute Liver Failure.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

290 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Qiangzhe ZhangDepartment of NanoEngineering and Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Diana DehainiDepartment of NanoEngineering and Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Yue ZhangDepartment of NanoEngineering and Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Julia ZhouDepartment of NanoEngineering and Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Xiangyu ChenDepartment of NanoEngineering and Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Lifen ZhangDepartment of NanoEngineering and Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Ronnie H FangDepartment of NanoEngineering and Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Weiwei GaoDepartment of NanoEngineering and Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Liangfang ZhangDepartment of NanoEngineering and Moores Cancer Center, University of California San Diego, La Jolla, CA, USA. zhang@ucsd.edu.ORCID http://orcid.org/0000-0003-0637-0654
University of California San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rheumatoid arthritis is a common chronic inflammatory disorder and a major cause of disability. Despite the progress made with recent clinical use of anti-cytokine biologics, the response rate of rheumatoid arthritis treatment remains unsatisfactory, owing largely to the complexity of cytokine interactions and the multiplicity of cytokine targets. Here, we show a nanoparticle-based broad-spectrum anti-inflammatory strategy for rheumatoid arthritis management. By fusing neutrophil membrane onto polymeric cores, we prepare neutrophil membrane-coated nanoparticles that inherit the antigenic exterior and associated membrane functions of the source cells, which makes them ideal decoys of neutrophil-targeted biological molecules. It is shown that these nanoparticles can neutralize proinflammatory cytokines, suppress synovial inflammation, target deep into the cartilage matrix, and provide strong chondroprotection against joint damage. In a mouse model of collagen-induced arthritis and a human transgenic mouse model of arthritis, the neutrophil membrane-coated nanoparticles show significant therapeutic efficacy by ameliorating joint damage and suppressing overall arthritis severity.

Indexed as

AnimalsArthritis, ExperimentalArthritis, RheumatoidCell MembraneCytokinesDisease Models, AnimalHumansHuman Umbilical Vein Endothelial CellsInflammationJointsMaleMice, Inbred ICRMice, TransgenicNanomedicineNanoparticlesNeutrophilsCytokines

Identifiers

PMID30177807
OpenAlexW2889191136

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.